Figure 6.
Treatment with the novel immune-enhancer inhibits tumor recurrence. (A) Mice were implanted with B16F10 tumor fragment on day 0 and treated three times intratumorally over 15 days. The primary tumor was surgically resected on day 15 under isoflurane anesthesia. (B) Tumor weight (in mg) measured on day 15 post B16F10 (2 mm3) implantation; each dot represents an individual tumor. Statistical analysis by Student’s t-test (mean±SE). (C) Mouse survival; mice were euthanized when the volume of recurrent tumors reached 1 cm3, statistical analysis by log-rank test. n=4, one representative of two similar experiments is shown. MCT, microcrystalline tyrosine.